Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.
Stock data | 2023 | Change |
---|---|---|
Price | $23.83 | N/A |
Market Cap | $2.54B | N/A |
Shares Outstanding | 106.75M | 1.26% |
Employees | 525.00 | N/A |
Shareholder Equity | 287.16M | -31.36% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | -12.41 | N/A |
P/S Ratio | 10.57 | N/A |
P/B Ratio | 8.86 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | -0.7288 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $240.74M | N/A |
Earnings | -$209.28M | N/A |
EPS | -1.92 | N/A |
Earnings Yield | -0.0806 | N/A |
Operating Margin | -0.8516 | N/A |
Net income margin | -0.8693 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $765.55M | N/A |
Total Debt | $115.17M | N/A |
Cash on Hand | $403.63M | N/A |
Debt to Equity | $1.67 | 154.72% |
Cash to Debt | $3.50 | -24.05% |
Current Ratio | $3.98 | 36.29% |